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Abstract
Background Aggressive medical management of cancer pa-
tients at the end of life (EOL) is an indicator of health services
quality. We evaluated the variations in EOL cancer therapy uti-
lization and in acute care hospital deaths across different types of
cancer within the setting of a regionalized cancer program.
Methods Intravenous chemotherapy and radiotherapy use
within the last 14 and 30 days of life was identified through
the Alberta Cancer Registry and then verified by chart review
for cancer decedents residing within 50 km of the Tom Baker
Cancer Centre between 2003 and 2010. Multivariable logistic
regression was used to examine variations in outcomes of
interest by cancer, adjusting for age and other factors in
prespecified models.
Results Of the 9863 decedents included in the study, 3.0 and
6.3 % received chemotherapy within the final 14 and 30 days
of life, respectively. In multivariable model, breast, hemato-
logical, and gynecological cancers were at least 2.5 times
more likely than other cancers to undergo EOL chemotherapy.
Radiotherapy was given to 4.6 % of decedents within 14 days
of death, but only 66 % (359/542 courses) were completed as
prescribed. Acute care admission within 14 days of death was
seen in 44 % of decedents and 34 % died in the hospital.
Conclusions In our regional cancer program, the intensity of
cancer therapies near the end of life varied considerably across
different cancer types. Such variations may be unwarranted. A
substantial proportion of cancer deaths occurred in the acute
care setting. Greater efforts to integrate palliative care in out-
patient cancer services are needed.
Keywords End-of-life care . Palliative oncology . Health
services research . Quality care
Background
In BThe Quality of Death: Ranking End-of-life Care across the
World^ report published in 2010, the Economist Intelligence
Unit remarked that Bthe ‘medicalisation’ of death in Canada
has engendered a culture where many people are afraid to raise
the topic of death^ [1]. This Bmedicalisation^ can be seen in
the growing intensity and aggressiveness of care involving
cancer therapies and acute care services for cancer patients
near the end of life. Cancer therapies, such as chemotherapy
and radiotherapy, are typically delivered within prescribed
protocols, with adverse effects deemed tolerable among pa-
tients with adequate functional performance or physiologic
reserve for physical recovery. But for those with end-stage
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disease, when management goals are geared towards symp-
tom control and comfort, the burden of treatment logistics and
side effects can be profound and can adversely impact the
quality of life.
Indicators of aggressive end-of-life cancer care and their
benchmarking for health system performance were first pro-
posed by Earle et al. [2, 3]. Overly aggressive care is evident
when measures such as chemotherapy given within last
14 days of life, new chemotherapy initiated within last 30 days
of life, and acute care hospital death exceed benchmarks.
Those metrics have been expanded to include end-of-life ra-
diotherapy and they allow examination of variations in their
utilization across regions and practice types in the USA [4–7].
Observations have also been reported for cancer decedents in
Ontario between 1993 and 2004, where variations in the ag-
gressiveness of therapies and services were observed across
five cancer types, with a trend towards increasing end-of-life
chemotherapy over time [8].
Oncology practice in Canada often involves multidisciplin-
ary care teams (as Btumor groups^ or Bdisease site groups^),
and clinical practice guidelines are usually concerned with
treatment indications for the average well patient, but relative-
ly limited in scope for the highly heterogeneous palliative
cancer population. Decisions to initiate or continue cancer
therapies in this setting may be driven by perceived rather than
established needs and benefits, which could lead to unwarrant-
ed variations in intensity and aggressiveness of care. Thus, we
were first interested in examining the use of end-of-life cancer
therapy and location of death for cancer patients managed
through our regional program, and second, we evaluated var-
iations in those outcomes across a broad range of cancer types,
controlling for some relevant factors. Confirmation of varia-
tions in the intensity of end-of-life care among different cancer
types would be informative to multidisciplinary practices and
facilitate attention on practice culture.
Materials and methods
Health system and study setting
Alberta has a multicultural population with 20 % visible mi-
nority and aboriginal population (Canada 2006 Census). Two
provincial comprehensive cancer centers provide services for
adult malignancies to a population of 3.5 million residents,
one of them in Calgary (Tom Baker Cancer Centre, TBCC).
TBCC processes about 5000 incident cancers per year, the
majority via outpatient visits for assessment and medical treat-
ment coordinated within multidisciplinary groups comprised
of medical specialists and other health professionals, for
which practice guidelines are developed and maintained [9].
However, palliative care specialists are not an integral part of
each multidisciplinary team in the outpatient setting; rather,
specialized palliative clinics (mainly for pain and symptom
management) run separately from subspecialized tumor-
specific clinics. This study was conducted solely within the
TBCC practice environment given data availability and that
standards were not yet in place to allow for province-wide
comparison. This study was approved by institutional review
board (Alberta Cancer Research Ethics Committee no. 25968).
Inclusion and exclusion
This is a retrospective health services study of decedents
deemed to have cancer as the main cause of death between
Jan 2003 and Dec 2010. Cases over 18 years of age at time of
cancer diagnosis were included, regardless of cancer stage at
diagnosis, if the residence of death or last known postal code
were within 50 km driving distance from TBCC, and their
deaths were located in the Calgary region, in order to limit
variations in utilization due to geographic distance [10]. For
the planned analyses, cases without cancer clinic registration
and rapidly fatal disease (cancer diagnosed within 1 month of
death) were excluded. Supplementary Fig. 1 summarizes the
selection.
Data sources and verification
The Alberta Cancer Registry (ACR) is a provincial cancer
registry with gold certification yearly by the North American
Association of Central Cancer Registries [11], maintained by
the Cancer Management Outcomes Research and Evaluation,
which also collects administrative data for service delivery
through provincial cancer care electronic medical records.
ICD-10 cause-of-death (vital statistics report) is recoded
where additional information is available to the ACR coder
and matched to registry ICDO-3 diagnosis (99 % match to
cancer site fine level). The ACR performed retrieval of all
recorded cancer decedents for this study in October 2012,
along with their radiotherapy and medical day care appoint-
ments within 30 days of death. For those cases with medical
day care treatments (i.e., systemic therapy), delivery of intra-
venous chemotherapy agents was further verified through
TBCC pharmacy dispensary records. (Only intravenous ther-
apies, including classical cytotoxic agents as well as monoclo-
nal antibodies and proteasome inhibitors, were included be-
cause of their expected toxicities and/or demand on health
system resources for administration.) Radiotherapy treatment
delivery were verified through treatment planning and elec-
tronic records for treatment volume, fractions prescribed, and
course completion. Chemotherapy delivered through any of
the three acute care facilities in Calgary was queried through
data linkage with hospital patient clinical information data-
bases (SCM) and regional data management department
(DIMR), using provincial unique health identifier. This link-
age also provides data on acute care admissions before death.
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Variables and outcomes of interest
The primary outcomes of interest in the study include end-of-
life (defined as within 14 days of death) chemotherapy and
radiotherapy utilizations (two separate outcomes) and death
occurring in acute care facility (hospital death). Secondary
outcomes include new chemotherapy within 30 days of death,
any chemotherapy within 30 days of death, and radiotherapy
within 30 days of death. Independent variables (covariates)
included cancer type, age at death, year of death, sex, disease
duration, and comorbidity as known predictors [8, 12]; in
addition, acute care admission within 14 days of death was
included as a covariate (yes/no) to approximate clinical acuity.
Registry cancers (73 sites) were recategorized into common
cancer types and their respective multidisciplinary tumor
groups. Disease duration, potentially a marker of aggressive
or advanced disease, was measured as time between date of
cancer diagnosis and date of death. Comorbidity was repre-
sented using the Deyo adaptation of the Charlson comorbidity
score, which looks at the last year of all inpatient/emergency
admissions and diagnosis data [13, 14]. Registry coding of
collaborative cancer stage (as opposed to clinical cancer stage)
was still undergoing implementation during the study period
and not sufficiently complete for inclusion as a covariate.
Statistical analysis
Outcomes and covariates were summarized by tables and fre-
quency distributions for categorical and continuous variables
as appropriate. Variations in primary outcomes by cancer type
were examined in prespecified multivariable logistic regres-
sion models. For end-of-life chemotherapy and end-of-life
radiotherapy outcomes, the seven covariates of interest were
cancer type, age, disease duration, sex, comorbidity, acute care
admission, and year of death. For modeling of hospital death
outcome, the same covariates were used, except that acute
care admission before death was replaced by exposure to
end-of-life therapy (chemotherapy and/or radiotherapy) to ex-
amine for association. Apart from the hypothesized cancer
type effect on outcomes of interest independent of
prespecified covariates, no additional hypothesis was tested;
statistical inferences are presented and interpreted based on
multivariable model point estimates (odds ratios, OR) and
95 % confidence limits (CL). Computed results are rounded
to two scientific digits in the text for simplicity. Because of
low event rates and numerous covariate levels, Firth’s penal-
ized likelihood method was used to correct for small sample
bias in the end-of-life chemotherapy and radiotherapymodels.
The absence of interaction between cancer type and age was
confirmed within respective models; no other interaction was
prespecified for testing. Model goodness-of-fit was checked
using Hosmer-Lemeshow partitioning. Statistical analyses
were performed using SAS 9.2 (SAS Inc., Cary, NC).
Results
Decedents’ characteristics
Between 2003 and 2010, 9863 decedents met the study inclu-
sion criteria, with a mean age of 70 years at time of death and a
slight preponderance towards male deaths. The top five cancer
causes of death by tumor groups were gastrointestinal (27 %),
lung (24 %), genitourinary (11 %), hematologic (9.1 %), and
breast cancer (8.8 %). Twenty-nine percent (2907/9863) of all
decedents were diagnosed between 1 and 6 months before
death. The characteristics of decedents and their respective
outcomes are summarized in Table 1 (outcomes by 18 cancer
types are provided in Supplementary Table 1).
End-of-life cancer therapy and location of death
Of the medical day care treatment encounters identified
through administrative records, only 64 % were verified to
have received chemotherapy. Including acute care in-patient
records of chemotherapy use (n=65), the overall end-of-life
chemotherapy utilization was 3.0 % (296/9863). The use of a
new chemotherapy agent within 30 days of death was 2.2 %
(220/9863), while any chemotherapy with 30 days of death
was 6.3 % (622/9863).
End-of-life radiotherapy use was accurately captured through
administrative data in 95% of cases, giving a rate of 4.6% (458/
9863); radiotherapy use within 30 days of death was seen in
10% (988/9863). Themost common indication for radiotherapy
was metastatic bone disease, followed by lung/mediastinal dis-
ease and brain metastases. Seventy-five percent of end-of-life
radiotherapy prescriptions involved multiple fractions of treat-
ments (almost always five or more fractions), but only 66 % of
all prescribed treatment volumes were completed as planned.
The characteristics of radiotherapy are summarized in Table 2.
Trends over the 8-year study period and by age for different
cancer types for end-of-life chemotherapy and end-of-life radio-
therapy are shown in Supplementary Figs. 2-5.
Forty-four percent (4362/9863) of decedents required acute
care admission within 14 days of death. With respect to the
location of death, the majority occurred in hospice facilities
(41 %, 4074/9863) and in acute care hospital setting (34 %,
3355/9863). Nineteen percent (1902/9863) of the decedents
had died at home and the remainder in long-term care (Table 1).
Variations in end-of-life cancer therapy and hospital death
across cancer types
The variations in end-of-life chemotherapy and radiotherapy
use across cancer types, controlling for age, disease duration,
and other covariates, are shown in Figs. 1 and 2. Compared to
other cancers, breast cancer (OR 3.3, CL 1.8–6.1), lymphoma-
myeloma (OR 3.3, CL 1.9–6.1), and gynecological cancers
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Cohort 9863 100 3.00 4.64 2.23 6.3 10.0 34.0
Age at death Median 71, mean 70, IQR 19, range 19–103
18–44 417 4.2 7.4 7.0 3.6 14.2 13.0 44.6
45–54 1098 11.1 5.4 6.7 4.0 10.5 13.6 38.3
55–64 1906 19.3 4.0 5.6 3.1 8.3 12.2 37.4
65–74 2508 25.4 3.6 4.7 2.8 7.8 10.8 36.0
75–84 2777 28.2 1.4 3.6 1.1 3.0 8.1 29.9
85+ 1157 11.7 0.3 2.7 0.2 0.8 4.9 26.1
Sex
%female, %male 9863 48.7, 51.3 3.0, 3.0 4.1, 5.2 2.4, 2.1 6.4, 6.2 9.4, 10.6 32.1, 35.9
Cancer type
GI 2682 27.2 2.8 1.6 1.8 6.9 4.0 29.9
Colorectala 1134 11.5 3.3 1.2 2.0 6.5 4.1 30.3
HepatoPanca 927 9.4 2.9 0.7 1.9 9.6 1.5 28.4
GI othersa 621 6.3 1.9 3.7 1.0 3.5 7.6 31.2
Lung 2364 24.0 2.2 8.3 2.2 4.3 17.6 34.3
GU 1099 11.1 1.6 3.9 1.1 3.6 8.6 34.8
Prostate 584 5.9 1.8 4.5 1.4 4.1 10.3 37.7
GU others 515 5.2 1.5 3.4 0.9 3.1 7.2 32.2
Hematologic 899 9.1 5.8 4.3 2.7 11.7 8.1 52.4
Leukemia 293 3.0 4.1 1.4 1.7 7.2 3.1 55.6
Lymphom-myelom 606 6.1 6.6 5.8 3.1 13.9 10.6 50.8
Breast 864 8.8 5.3 3.9 3.5 9.3 10.2 32.3
Gyne 542 5.5 4.6 2.6 4.6 9.2 5.4 34.1
CNS 355 3.6 0.0 4.2 0.0 0.3 7.3 19.2
Head and neck 306 3.1 3.3 5.9 1.6 5.9 14.7 38.9
Others 752 7.6 2.4 7.3 3.3 5.7 14.4 31.9
Disease duration Median 1.1 years, mean 2.6, IQR 2.5, range 0.1–50.3
1–3 months 1553 15.8 4.0 8.8 4.1 7.9 17.5 40.8
3–6 months 1354 13.7 3.4 5.5 2.3 7.8 10.8 34.6
6–12 months 1792 18.2 2.7 4.2 1.6 6.0 9.3 32.6
1–2 years 1819 18.4 2.6 3.3 2.0 5.7 7.9 30.8
2–5 years 1831 18.6 3.1 3.6 2.0 6.2 8.6 32.3
≥5 years 1514 15.4 2.4 3.0 1.5 4.6 6.9 34.2
Year of death
2003 1080 11.0 4.4 6.0 3.2 8.2 11.0 38.2
2004 1162 11.8 2.5 5.1 2.1 6.2 10.4 38.3
2005 1163 11.8 3.0 5.6 2.4 5.6 11.9 33.1
2006 1276 12.9 2.6 4.1 2.0 6.0 9.6 34.5
2007 1269 12.9 2.5 5.3 1.5 6.2 10.6 32.9
2008 1295 13.1 3.5 4.8 2.1 6.4 10.7 32.1
2009 1320 13.4 2.6 3.7 2.1 5.7 9.5 31.7
2010 1298 13.2 3.1 3.0 2.6 6.5 6.9 32.4
Hospitalization within 14 days of death
Yes 4362 44.2 4.8 8.6 3.4 10.1 16.3 70.8b
No 5501 55.8 1.6 1.5 1.3 3.3 5.0 4.8
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(OR 2.5, CL 1.3–4.8) demonstrate strong tendencies towards
the use of end-of-life chemotherapy; colorectal cancer shows a
relatively modest effect (OR 1.8, CL 1.0–3.3). With respect to
end-of-life radiotherapy, because melanoma demonstrated a
high event rate (supp. Table 1), it was made a separate level
in the regression model (OR 1.9, CL 1.0–3.5). Most cancer
types have a similar use of end-of-life radiotherapy.
Gastrointestinal cancers (ORs 0.10 to 0.54) and leukemias
(OR 0.20) demonstrate very low tendencies for end-of-life
radiotherapy, consistent with the infrequent clinical indication
for this modality in advanced stages of these diseases.
In both multivariable models, acute care admission is
strongly associated with (OR 2.6, CL 2.0–3.4 and OR 6.0,
CL 4.7–7.7, respectively) end-of-life cancer therapy. Younger
age and decedents with a short duration of disease (1–
6 months) are also more likely to be given cancer therapy at
end-of-life. Higher comorbidity scores were associated with
less end-of-life radiotherapy. Male decedents are more likely
than female to have undergone end-of-life chemotherapy (OR
1.3, CL 1.01–1.8). A trend towards a reduction of end-of-life
radiotherapy in the second half of the study (2007–2010) can
be appreciated (OR 0.86, CL 0.71–1.05), but no time period
effect is apparent for end-of-life chemotherapy.
The effects of cancer type and covariates on hospital death
are presented in Fig. 3. Most cancer types show similar tenden-
cies towards hospital death, the exception being a strong tenden-
cy among hematological cancer decedents to die in hospital
(leukemias OR 3.0, CL 2.2-4.0; lymphomas-myelomas OR
2.2, CL 1.7-2.8). Notably, exposure to either chemotherapy or
radiotherapy at end-of-life occurred in 7.4 % (732/9863) of the
decedents; this factor is the strongest predictor for dying in hos-
pital (OR 5.1, CL 4.3–6.0). Seventy-seven percent (566/732) of
the end-of-life cancer therapy occurred during hospital admis-
sion or within close temporal proximity of each other (both
events occurring within 2 weeks of death); rarely did the dece-
dents receive both chemotherapy and radiotherapy (0.2 %, 22/
9863). Older patients were less likely to die in hospital (OR 0.83,
CL 0.80–85, per decade increase). Higher comorbidity scores
increased the probability of hospital death. A modest time trend
was observed, with a lower tendency towards hospital deaths in























Comorbidity (Charlson score, Deyo adaptation; excludes cancer diagnosis)c
0 5987 60.7 3.1 4.7 2.4 6.5 10.3 29.1
1 2060 20.9 2.7 4.9 2.1 6.2 10.6 37.5
≥2 1814 18.4 3.0 4.2 1.9 5.9 8.4 46.2
Place of death
Hospital 3355 34.0 6.8 9.3 4.5 12.3 15.9 –
Hospice 4074 41.3 0.6 1.9 0.7 2.6 7.0 –
Home 1902 19.3 2.2 3.1 2.0 5.2 8.0 –
Long-term care 532 5.4 0.6 1.7 0.2 0.8 3.0 –
a Colorectal includes anal carcinomas; HepatoPanc includes the liver, biliary tract, and pancreas; GI others include intestinal and upper GI cancers
b 29.2 % of 4362 admitted patients were discharged from hospital before death: hospice 22.4 %, home 5.3 %, long-term care 1.5 %
cMissing comorbidity scores in two cases
Table 2 Summary of end-of-life radiotherapy prescriptions
Number Col%
No. of radiotherapy prescriptions per decedent (N=458)
1 371 81
2–3 86 19
No. of prescriptions (N=542) completed as planned
359/542 66
No. of fractions per prescription (N=542)
Single 103 19
2–5 (mostly 5) 226 42




Simple (e.g., single-field) 403 74







One prescription per radiotherapy volume of treatment; some patients
require multiple volumes of radiotherapy for symptom palliation
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Summary of findings and interpretation
In this health services evaluation of end-of-life cancer care at
an urban Canadian tertiary referral center, we found that while
end-of-life chemotherapy and end-of-life radiotherapy rates
were low (3.0 and 4.6 %, respectively), the rate of new chemo-
therapy use in the final month of life (2.2 %) and the rate of
hospital death (34 %) suggest that end-of-life care was still ag-
gressive. The rate of end-of-life chemotherapy for deaths be-
tween 2003 and 2010 in our study is comparable to that reported
for Ontario (2.9 % end-of-life chemotherapy by 2004) [8], but
variations in the utilization of cancer therapy were considerable
across different cancer types and the variations were independent
of other relevant variables. End-of-life cancer therapy is itself a
Fig. 1 Multivariable logistic regression of factors associated with end-of-
life chemotherapy. Age as continuous variable, OR 0.66 per decade
increase. Comorbidity score missing for two cases; Comorbidity B2^
covers scores 2 to 8. Cancer CNS has zero EOL chemo event (OR=
0.05, 95 % Cl <0.001 to 0.37). Cancer GI CR colorectal and anus;GI
HP hepatobiliary and pancreas; GI Oth upper GI and other GI cancers;
Gyne ovarian, cervical, uterine, and other female genital organs; H&N
head and neck; He.Leuke hematology leukemias; He.Ly-Myel
hematology lymphomas, myelomas, and immune disorders; Dis_
Duration disease duration from date of initial cancer diagnosis to date
of death; Acute_Care admission to acute care facility within 14 days of
death; H-L Hosmer-Lemeshow goodness-of-fit test; cov covariates; df
degrees of freedom
Fig. 2 Multivariable logistic
regression of factors associated
with end-of-life radiotherapy.
Model includes additional level of
Cancer:Melanmelanoma. Age as
continuous variable, odds ratio
0.82 (95 % CI 0.76 to 0.88) per
decade increase. See Fig. 1 for
abbreviations
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strong predictor of hospital death. Even though the rate of
dying in acute care facility appears lower than the national
average of 45 % reported for 2011–2012 [15], the 34 % rate
of hospital-based death is far from the expressed preference by
Albertans to spend end-of-life care at home (71 % preferred to
be at home near death; 7 % preferred hospital) [16]. The ob-
servation that 44 % of decedents requiring acute care hospi-
talization within 2 weeks of death is concerning for unmet
needs among palliative cancer outpatients.
We observed a two- to threefold increase in end-of-life
chemotherapy use among breast, hematologic, and gyneco-
logical cancers compared to other tumor groups. AsWennberg
et al. propose [17], if these variations reflect genuine differ-
ences in the informed care preferences of the patients, they
may be considered warranted. But based on Wilson et al.
[16], one would surmise there are gaps between treatment
intensity and end-of-life preferences in our practice, gaps that
are not explained by age, comorbidity, and apparent acuity as
demonstrated in the multivariable models. The observed varia-
tions in end-of-life cancer therapy in this regional cancer pro-
gram may be unwarranted, and there are strong ethical [18] and
economic [19] motivations for closer examinations of practice
patterns and decision making processes. In addition, such vari-
ations are a source of concern for future cancer management, if
they are driven by supply-sensitive care. As new discovery re-
search and drug developments continue, more systemic agents
will become available as usual care to the variousmultidisciplin-
ary tumor groups (most recently, tyrosine kinase inhibitors of
various molecular targets). A likely consequence would be an
increase in cancer therapy use (and not limited to chemotherapy)
in the palliative and end-of-life setting; that is, a normalization of
aggressiveness in end-of-life cancer care. In some respects, the
notable overprescription of radiotherapy fractions in our study
(34 % of prescriptions failed to finish as intended) may be a
reflection of that normalization. Such overprescription of radio-
therapy has been observed elsewhere [6, 7] and raises further
questions about the supply-sensitive nature of clinical decision
making and prescription choices near end-of-life.
We also observed a high acute care admission rate (44 %)
before death and a strong association with end-of-life cancer
therapy during admission. While further studies are needed to
evaluate the nature of the acuity or distress leading to acute
care admissions, judicious use of survival prediction tools and
prognostic factors, such as those recommended by the Euro-
pean Association of Palliative Care [20], may help identify
patients in the final weeks of life for more thorough evaluation
of palliative care needs. Decline in performance status over
repeated clinic visits [21] may serve as a trigger for reevalua-
tion of goals of therapy and transition to end-of-life care
among palliative outpatients. Engagement with patient and
family in advance care planning is vital to facilitate their un-
derstanding of prognosis, to review their end-of-life prefer-
ences, and to manage their expectations, including issues of
continuity, treatment discontinuation, and closure [22–24].
A modest time trend was observed towards fewer hospital
deaths after 2007 in our study. The time period corresponds to
new hospice facilities and initiatives in goals of care designa-
tion in acute care. With accumulating evidence towards inte-
grating palliative care services in the ambulatory oncology
setting [25, 26], future cancer services should see tangible
benefits from coordinated efforts to integrate palliative care
principles within multidisciplinary tumor group structures.
Our group has reported a reduction in end-of-life radiotherapy
use after an integrated palliative oncology clinic became avail-
able for patients with newly diagnosed brain metastases [27].
In addition to reviewing prognosis, treatment goals, and
Fig. 3 Multivariable logistic
regression of factors associated
with dying in hospital. Age as
continuous variable, OR 0.83
(95 % CI 0.80 to 0.85) per decade
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expectations of functional decline, acknowledging psychoso-
cial and existential distress is an essential component of care
through this integrated palliative oncology clinic.
Study limitations
Our study was conducted on decedents managed in an urban,
tertiary cancer care setting, and the results are not necessarily
representative of rural populations. Clinical factors such as
disease extent, prior therapies, symptom distress, and goals
of care designation were not determined, and patient hetero-
geneity has not been described by such factors. As such, the
clinical indications and appropriateness of cancer therapy or
acute care admission could not be ascertained. The observed
chemotherapy use in acute care facilities was low (0.6 %) but
may be underreported by the hospital data management sys-
tem before electronic drug ordering was implemented in 2007.
End-of-life chemotherapy delivery rate, upon verification,
was 35 % lower than that identified through administrative
data query. To extend our study province-wide, efforts to in-
tegrate data from hospital pharmacy, cancer clinic pharmacy,
and other parts of cancer services will be essential. Other
indicators of aggressive end-of-life care, such as repeated
emergency room visits, admission to ICU, and repeated hos-
pital admissions in the final month of life, are being examined.
Those results, including the potential impact of prior palliative
care consultations and community palliative home care expo-
sure before the final month of life, will be reported separately.
Conclusions
Cancer patients interact with a highly specialized and
intervention-oriented health care system. End-of-life care is often
medicalized and intense, and variations in that intensity among
different types of cancer may be unwarranted. Multidisciplinary
cancer teams are positioned to guide a complex and evolving
cancer care program, but enhancement of palliative care training
and integration of palliative services are needed to help maintain
the balance between interventional and comfort measures in pa-
tients through the final phases of their cancer journey.
Acknowledgments The authors thank the following individuals for
their advice and contributions to this study: Tom Snodgrass for
consultative input on Alberta Cancer Registry data reporting and
queries, Margaret Ngo and Carole Chambers for TBCC pharmacy
chemotherapy delivery verification, Kevin Lonergan and Cathy Askin for
data queries through acute care data management (SCM/DIMR), and Dr.
Trafford Crump and Dr. Marc Kerba for insightful comments on the
manuscript.
Conflict of interest Drs. Grendarova, Sinnarajah, Trotter, andWu have
no conflict of interest to declare. Dr. Card has provided consultant/
advisory services to Pfizer and Bayer companies unrelated to this study.
Funding Dr. Grendarova is enrolled in the Clinical Investigator Pro-
gram, University of Calgary, funded by the Alberta Cancer Foundation
Clinical Fellowship Dr. Anthony Fields Award.
Open Access This article is distributed under the terms of the Creative
Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and the source are credited.
References
1. The quality of death: ranking end-of-life care across the world. A
report from the Economist Intelligence Unit commissioned by Lien
Foundation (2010). Available: http://www.eiu.com/site_info.asp?
info_name=qualityofdeath_lienfoundation&page=noads&rf=0
2. Earle CC, Neville BA, Landrum MB et al (2005) Evaluating claims-
based indicators of the intensity of end-of-life cancer care. Int J Qual
Health Care 17(6):505–509
3. Earle CC, Landrum MB, Souza JM et al (2008) Aggressiveness of
cancer care near the end of life: is it a quality-of-care issue? J Clin
Oncol 26(23):3860–3866
4. Morden NE, Chang CH, Jacobson JO et al (2012) End-of-life care for
Medicare beneficiaries with cancer is highly intensive overall and
varies widely. Health Aff 31(4):786–796
5. Guadagnolo BA, Liao KP, Elting L et al (2013) Use of radiation
therapy in the last 30 days of life among a large population-based
cohort of elderly patients in the United States. J Clin Oncol 31(1):80–
87
6. Kapadia NS, Mamet R, Zornosa C et al (2012) Radiation therapy at
the end of life in patients with incurable nonsmall cell lung cancer.
Cancer 118(17):4339–4345
7. Toole M, Lutz S, Johnstone PA (2012) Radiation oncology quality:
aggressiveness of cancer care near the end of life. J Am Coll Radiol
9(3):199–202
8. Ho TH, Barbera L, Saskin R et al (2011) Trends in the aggressiveness
of end-of-life cancer care in the universal health care system of
Ontario, Canada. J Clin Oncol 29(12):1587–1591
9. Alberta Health Services cancer guidelines, information for health
professionals: Available: http://www.albertahealthservices.ca/
cancerguidelines.asp. Accessed Aug 2014
10. Danielson B, Winget M, Gao Z et al (2008) Palliative radiotherapy
for womenwith breast cancer. Clin Oncol (R Coll Radiol) 20(7):506–
512
11. North American Association of Central Cancer Registries: Available:
http://www.naaccr.org/Certification/WhoisCertified.aspx. Accessed
Aug 2014
12. Barbera L, Paszat L, Chartier C (2006) Indicators of poor quality end-
of-life cancer care in Ontario. J Palliat Care 22(1):12–17
13. Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comor-
bidity index for use with ICD-9-CM administrative databases. J Clin
Epidemiol 45:613–619
14. Quan H, Sundararajan V, Halfon P et al (2005) Coding algorithms for
defining comorbidities in ICD-9-CM and ICD-10 administrative da-
ta. Med Care 43:1130–1139
15. Canadian Institute for Health Information. End-of-life hospital care
for cancer patients. 2013; Available at: https://secure.cihi.ca/free_
products/Cancer_Report_EN_web_April2013.pdf. Accessed 1 May
2013
16. Wilson DM, Cohen J, Deliens L et al (2013) The preferred place of
last days: results of a representative population-based public survey. J
Palliat Med 16(5):502–508
3066 Support Care Cancer (2015) 23:3059–3067
17. Wennberg JE, Fisher ES, Skinner JS (2002) Geography and the de-
bate over medicare reform. Health Aff. doi:10.1377/hlthaff.w2.96
18. Moulton B, King JS (2010) Aligning ethics with medical decision-
making: the quest for informed patient choice. J Law Med Ethics
38(1):85–97
19. Lee EO, Emanuel EJ (2013) Shared decision making to improve care
and reduce costs. N Engl J Med 368(1):6–8
20. Maltoni M, Caraceni A, Brunelli C et al (2005) Prognostic factors in
advanced cancer patients: evidence-based clinical recommenda-
tions—a study by the Steering Committee of the European
Association for Palliative Care. J Clin Oncol 23(25):6240–6248
21. Sutradhar R, Barbera L (2014) A Markov multistate analysis of the
relationship between performance status and death among an ambu-
latory population of cancer patients. Palliat Med 28(2):184–190
22. Wright AA, Zhang B, Ray A et al (2008) Associations between end-
of-life discussions, patient mental health, medical care near death,
and caregiver bereavement adjustment. JAMA 300(14):1665–1673
23. Back AL, Young JP, McCown E et al (2009) Abandonment at the end
of life from patient, caregiver, nurse and physician perspectives. Arch
Intern Med 169(5):474–479
24. Heyland DK, Barwich D, Pichora D et al (2013) Failure to engage
hospitalized elderly patients and their families in advance care plan-
ning. JAMA Intern Med 173:778–787
25. Temel JS, Greer JA, Muzikansky A et al (2010) Early palliative care
for patients with metastatic non-small-cell lung cancer. N Engl J Med
363:733–742
26. Smith TJ, Temin S, Alesi ER et al (2012) American Society of
Clinical Oncology provisional clinical opinion: the integration of
palliative care into standard oncology care. J Clin Oncol 30(8):
880–887
27. JungH, Sinnarajah A, Enns B et al (2013)Managing brainmetastases
patients with and without radiotherapy: initial lessons from a team-
based consult service through multidisciplinary integrated palliative
oncology clinic. Support Care Cancer 21:3379–3386
Support Care Cancer (2015) 23:3059–3067 3067
